109 results
Page 4 of 6
8-K
EX-99.1
9nzig5
5 Aug 19
First European hypercare launch site initiated following CE mark approval
8:27am
8-K
EX-1.1
wu6 eadwt1gdym
31 May 19
Entry into a Material Definitive Agreement
4:20pm
424B5
5d3nlzw 0gr1zbl
31 May 19
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
wf4si1yr
28 May 19
CE mark received on the initial Immunohematology microarray in April 2019
7:34am
8-K
EX-99.1
rkj2wydudf63k
31 Jan 19
Development data provides positive results for extended IH microarray panel
8:25am
8-K
EX-1.1
4tqbz6lvczt5 foxb
11 Dec 18
Entry into a Material Definitive Agreement
4:20pm
424B5
w15e ndqfnp
7 Dec 18
Prospectus supplement for primary offering
5:24pm
424B5
qzgvj00 utzaz
6 Dec 18
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
3od7x kj11qf1lezkbge
5 Nov 18
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
6:18am
8-K
EX-99.1
7njph3we
6 Aug 18
Results of Operations and Financial Condition
4:15pm
8-K
EX-99.1
8025 w5hjlll3
29 May 18
Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQTM European Field Trials
6:37am